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1. INTRODUCTION 
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and lethal disease 
associated with an extremely poor prognosis in most patients (Velme et al., 2007). The 
median survival of patients with IPF from the time of diagnosis is only 2 to 4 years, which is 
shorter than that of patients with various types of cancers (Meltzer and Noble, 2008). A 
prominent pathological characteristic of IPF is the formation of fibrotic foci consisting of 
myofibroblasts and the aberrant expression of extracellular matrix (ECM) proteins in the 
lungs, and the extent of fibrotic foci has been correlated with the mortality of patients (King 
et al., 2001; Kendall and Feghali-Bostwick, 2014). As Fig. 1 shows, the progression of 
fibrotic formation is associated with the accumulation of fibroblasts and promotion of 
fibroblast to myofibroblast differentiation (FMD) and also results in dyspnea due to the 
excessive scarring of lung tissue (King et al., 2011). Therefore, myofibroblasts are 
responsible cells in fibrogenesis under pathological environments in the lung. 
Myofibroblasts are characterized by the up-regulation of α-smooth muscle actin (αSMA), 
fibronectin, and collagens (Hashimoto et al., 2001; Hu et al., 2003). Among the many factors 
and cytokines regulating lung fibrosis, transforming growth factor-β1 (TGF-β1) is a critical 
factor promoting FMD. TGF-β1 was previously shown to be up-regulated in the lungs of 
patients with IPF, indicating that TGF-β1 is a strong profibrotic factor (Evans et al., 2003). 
However, blocking TGF-β1 itself is not realistic: TGF-β1 also plays important roles in cell 
growth, differentiation, apoptosis, migration, immune cell functions, and TGF-β1-knock out 
mice die due to severe systemic inflammation (Shull et al., 1992). Therefore, revealing the 
responsible signaling in fibrosis would be required. As one of the in vitro assay models for 
examining the anti-profibrotic effects of various agents, the measurement of TGF-β1-induced 
FMD is a useful strategy. In addition, the inhibition of FMD may contribute to the 
development of fundamental treatments for IPF.  
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Although there is no effective pharmacological therapy to improve the survival of patients 
with IPF, the optimal strategy for the management of patients by steroid and/or 
immunosuppressants as well as clinical trials for new drugs have been actively investigated 
(du Bois, 2010; Staitieh, 2015). The beneficial effects of immunosuppressant-based 
combination therapy such as prednisone/azathioprine (AZA) and 
prednisone/AZA/N-acetylcysteine (PANTHER) on IPF have been proven in some cases 
(Raghu et al., 1991; American Thoracic Society, 2000). Similarly, the acute exacerbation of 
IPF defined as the acute and clinically significant deterioration of an unidentifiable cause in 
patients with IPF is ameliorated by immunosuppressants (Sakamoto et al., 2010). However, it 
currently remains unclear whether immunosuppressant-based therapies inhibit fibrosis, i.e., 
myofibroblast formation. On the other hand, increased risks of death and hospitalization were 
recently reported in PANTHER-IPF studies, and the survival of patients with the acute 
exacerbation of IPF previously treated with immunosuppression was less than that of never 
treated patients (Idiopathic Pulmonary Fibrosis Clinical Research Network, 2012; Papiris et 
al., 2015). Thus, the effectiveness of immunosuppressant-based combination therapy for IPF 
patients is controversial. An evaluation of the effects of immunosuppressants on fibrosis may 
lead to the discovery of new indications such as anti-profibrotic actions. Furthermore, studies 
are needed in order to elucidate whether the intratracheal administration of estimated 
anti-profibrotic immunosuppressants is effective in an experimental IPF model for the 
following reasons: 1) a lower dose of an immunosuppressant than the usual dose systemically 
administered may be directly delivered to the fibrotic wounds associated with alveolar wall 
damage, which may increase therapeutic efficacy. 2) To the best of our knowledge, the effects 
of the intratracheal administration of immunosuppressants on pulmonary fibrosis in vivo have 
not yet been assessed in detail. 
We herein screened the anti-FMD effects of various types of immunosuppressants in vitro, 
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and showed that cyclosporine A (CsA) inhibited TGF-β1-induced myofibroblast formation by 
enhancing the protein degradation of hypoxia-inducible factor (HIF)-1α. Similarly, CsA and 
the inhibition of HIF-1α dedifferentiated myofibroblast-like cells (MyoLCs) derived from 
patients with pulmonary fibrosis. Furthermore, the intratracheal administration of CsA or 
HIFi, even at the early fibrotic stage of bleomycin (BLM)-induced lung injury, markedly 
ameliorated the development of lung fibrosis. 
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2. ABBREVIATIONS 
αSMA, α-smooth muscle actin; AZA, azathiopurine; BALF, bronchoalveolar lavage fluid; 
BLM, bleomycin; CN, calcineurin; CsA, cyclosporine A; DAPI, 
4’6’-diamino-2-phenylindole; DMEM, Dulbecco’s modified Eagle’s medium; dpi, days post 
instillation; ECM, extracellular matrix; EMT, epithelial-mesenchymal transition; FMD, 
fibroblast to myofibroblast differentiation; GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase; HE, hematoxylin-eosin; HIF, hypoxia-inducible factor; HIFi, 
hypoxia-inducible factor-1α inhibitor; IPF, idiopathic pulmonary fibrosis; MT, Masson’ s 
trichrome; MyoLCs, myofibroblast-like cells; PFD, pirfenidone; PHD, prolyl hydroxylase; 
pSmad3, phosphorylated Smad3; qPCR, quantitative polymerase chain reaction; S100A4, 
S100 calcium-binding protein A4; SIS3, Smad3 inhibitor; TGF-β1, transforming growth 
factor-β1; VHL, von Hippel-Lindau 
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3. MATERIALS AND METHODS 
Cell culture.  Human fetal lung fibroblasts, HFL-1 cells and WI-38 cells were purchased 
from the American Type Culture Collection (Manassas, VA, USA) and RIKEN Cell Bank 
(Tsukuba, Ibaraki, Japan), respectively. Cells were maintained in culture medium, Dulbecco’s 
modified Eagle’s medium (DMEM) (Wako, Tokyo, Japan) supplemented with 10% 
heat-inactivated fetal bovine serum (Life Technologies, Carlsbad, CA, USA), and 0.1 mg/ml 
streptomycin and 100 U/ml penicillin (Meiji Seika, Tokyo, Japan) at 37˚C in a humidified 
atmosphere (5% CO2). In some experiments, the human lung adenocarcinoma epithelial cell 
line, A549 (European Collection of Cell Cultures, Salisbury, UK) was used to measure 
TGF-β1-induced decreases in E-cadherin levels, a marker of epithelial cells, in the absence or 
presence of a designated agent. 
 
In vitro FMD assay.  After 24 h of serum deprivation in DMEM, cells were treated with 10 
ng/ml human recombinant TGF-β1 (PeproTech, Rocky Hill, NJ, USA) for a further 48 h in 
the absence or presence of the designated agent. Control cells were subjected to serum 
deprivation for 72 h. Cell lysates were subjected to immunoblotting to estimate the 
expression of FMD markers. In some experiments, serum-deprived cells were treated with 
TGF-β1 for short time periods in the absence or presence of the designated agent, and cell 
lysates were subjected to measurements of phosphorylation signaling and protein levels. 
Regarding the effects of immunosuppressants and inhibitors for signaling molecules on 
FMD, the following designated concentrations of the reagent were applied to HFL-1 cells or 
WI-38 cells under TGF-β1-induced FMD, and the levels of αSMA in cells were estimated by 
immunoblotting: CsA (a calcineurin (CN) inhibitor, Enzo Life Science, Farmingdale, NY, 
USA), FK506 (a CN inhibitor, LC Laboratories, Woburn, MA, USA), cyclophosphamide (a 
DNA alkylating agent, Sigma-Aldrich, St. Louis, MO, USA), AZA (an inosine 
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monophosphate dehydrogenase inhibitor, Santa Cruz Biotech., Santa Cruz, CA, USA), 
rapamycin (a mammalian target of rapamycin (mTOR) inhibitor, LC Laboratories), 
hydrocortisone (a glucocorticoid class of steroid hormones, Wako), pirfenidone (PFD, an 
anti-fibrotic drug for the treatment of IPF, Shionogi & Co., LTD., Osaka, Japan), 
6,7-dimethoxy-2-((2E)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridine-3-yl-prop-2-enoyl)-
1,2,3,4-tetrahydroisoquinoline (SIS3, a Smad3 inhibitor, Calbiochem, La Jolla, CA, USA), 
methyl 3-[[2-[4-(2-adamantyl)phenoxy]acetyl]amino]-4-hydroxybenzoate (a HIF-1α inhibitor 
(HIFi), Santa Cruz).  
 
Immunoblotting.  Cultured cell-derived lysates and lung-derived protein samples were 
electrophoresed on 10% SDS-PAGE and transferred to PVDF membranes. Washed and 
blocked membranes were reacted with the following primary antibodies (for antibodies’ 
information, see Table1) at room temperature for 1 h. After washing, the membranes were 
incubated with a HRP-conjugated secondary antibody (1:2000-1:4000, anti-mouse IgG or 
anti-rabbit IgG) at room temperature for 1 h. Immunoreactive bands were visualized using a 
chemiluminescent reagent, the SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Fisher Scientific, Waltham, MA, USA). Results were analyzed using a LAS-1000 plus system 
equipped with Science Lab software (Fuji-film, Tokyo, Japan). The intensity of 
chemiluminescence was measured with NIH ImageJ software. 
 
RNA interference.  WI-38 cells were transfected with siHIF-1α using Lipofectamine 
RNAiMAX (Invitrogen, Carlsbad, CA, USA) in Opti-MEM (Thermo Fisher Scientific) for 6 
h and incubated in culture medium a further 24 h. After 24 h of serum deprivation, cells were 
treated with TGF-β1 for 48 h, and these cell lysates were subjected to immunoblotting for 
αSMA. 
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Nuclear translocation of pSmad3.  WI-38 cells were treated with TGF-β1 in the absence or 
presence of HIFi (5 µM), fixed, and subjected to an immunofluorescent study. Cells were 
incubated with the anti-pSmad3 antibody, following by the reaction with Alexa Flour 
488-conjugated anti-rabbit IgG, and observed under a confocal fluorescence microscope 
(LSM 780, Zeiss, Oberkochen, Germany). Nuclei were stained with 4’6’-diamino- 
2-phenylindole (DAPI). 
 
Assay for cellular CN activity.  Cellular CN activity was examined using an assay kit (Enzo 
Life Sci, Farmingdale, NY, USA). In brief, WI-38 cells were cultured with DMEM for 24 h, 
and treated with 10 µM CsA or 10 µM FK506 for a further 30 min. Washed cells were 
suspended in the lysis buffer, lysates after centrifugation were applied to a column to remove 
free phosphate, and CN activity was measured according to the manufacturer’s protocol. 
 
Total RNA isolation and quantitative polymerase chain reaction (qPCR).  After 24 h of 
serum deprivation in DMEM, cells were treated with TGF-β1 for a further 24 h in the 
absence or presence of the designated agent. Total RNA was isolated from WI-38 cells using 
Isogen II (Nippon Gene, Toyama, Japan) according to manufacturer’s instructions. The total 
RNA samples (0.5 µg) were reverse-transcribed into cDNAs with ReverTraAce® qPCR RT 
Master Mix with gDNA Remover (TOYOBO, Osaka, Japan). Relative gene expressions were 
quantified in Pikoreal 96 (Thermo Scientific) by using PowerUp™ SYBR™ Green Master 
Mix (Thermo Scientific). Expression levels of target gene were corrected for Gapdh 
expression levels by using ΔΔCt method (Pikoreal software 2.2). The primer sequences were 
as follows: Acta2 (5’-CTGGCATCGTGCTGGACTCT-3’ and 
5’-GATCTCGGCCAGCCAGATC-3’), FN1 (5’-GAGCTATTCCCTGCACCTGATG-3’ and 
5’-CGTGCAAGGCAACCACACT-3’), and Gapdh (5’-GCACCGTCAAGGCTGAGAAC-3’ 
10 
 
and 5’- TGGTGAAGACGCCAGTGGA-3’). Amplification parameters were as follows: one 
cycle of 50˚C for 2 min and 95˚C for 2 min, followed by 40 cycles of 95˚C for 15 s, 55˚C 15 
s, and 72˚C 60 s. 
 
Degradation assay of transiently overexpressed HIF-1α.  HIF-1α cDNA (GenBank 
Accession No: BC012527, Thermo Fisher Scientific) was subcloned into an expression 
vector with the CMV promoter. HEK293T cells were transiently transfected with the vector 
for HIF-1α using Lipofectamine 2000 (Invitrogen) in Opti-MEM for 6 h and cultured in 
culture medium for a further 24 h. Cells were then treated with 10 µM CsA, 10 µM MG132 
(a proteasome inhibitor, Merck Millipore, Billerica, MA, USA), or 10 µM CsA plus 10 µM 
MG132 for 30 min. 
 
Primary culture of human lung MyoLCs.  Lung tissue from a 19-year-old male patient who 
underwent lung transplantation due to severe pleuroparenchymal fibroelastosis was obtained 
after surgery. The patient provided informed consent, and the study was approved by the 
Ethics Committee of Chiba University, Graduate School of Medicine and Hospital. Lung 
tissue was minced into small pieces. After rinsed with phosphate-buffered saline (PBS), 
pieces were incubated in DMEM supplemented with 1 mg/ml collagenase type I 
(Worthington, Lakewood, NJ, USA), 0.5 mg/ml dispase (Life Technologies), 2 U/ml DNase 
(QIAGEN, Valencia, CA, USA), 0.1 mg/ml streptomycin, and 100 U/ml penicillin at 37˚C for 
15 min with gentle shaking. After washing twice with DMEM, the resulting pieces 
transferred to an 80-cm2 culture flask (Thermo Fisher Scientific) were dipped with culture 
medium and cultured at 37˚C and 5% CO2. The outgrowth of cells was monitored weekly 
with changes in culture medium every 4 days. When the flask reached confluence, outgrown 
cells were harvested as cells at passage 0. Expanded cells at passage 3 were used in 
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experiments.  
In the immunofluorescent study, cells were incubated with the mouse anti-αSMA 
antibody, the rabbit anti-S100 calcium-binding protein A4 (S100A4) antibody, or mouse 
anti-fibronectin antibody, following by a reaction with Alexa Flour 594-conjugated 
anti-mouse IgG and Alexa Fluor 488 phalloidin, and were then observed under a fluorescence 
microscope (Axio Imager A2, Zeiss, Oberkochen, Germany). Phalloidin was used to detect 
actin filaments. Nuclei were stained with DAPI. 
 
Animals.  Male C57BL/6J mice were purchased from Clea Japan (Tokyo, Japan) and were 
used at 8-12 weeks of age. Animals were housed in the Animal Resource Facility of Chiba 
University under pathogen-free conditions and cared for according to the animal care 
guidelines of Chiba University. Experiments were performed according to an animal protocol 
approved by the Animal Welfare Committee of Chiba University. 
 
BLM-induced lung injury model.  Mice under anesthesia were given a single intratracheal 
injection of BLM hydrochloride (3 mg/kg, Nippon Kayaku, Tokyo, Japan) dissolved in saline, 
using a Microsprayer® atomizer (PennCentury, Philadelphia, PA, USA). Control mice 
received a sham treatment with saline. At the designated days post-instillation (dpi) of BLM, 
mice under anesthesia were intracardially perfused with ice-cold PBS to thoroughly wash out 
blood cells in the lungs and were then sacrificed. The left lung lobes were separated from the 
trachea and main bronchi. The upper parts were homogenized and centrifuged at 4˚C to 
prepare supernatants as protein samples for immunoblotting. The lower parts of the lobes 
were fixed, dehydrated, and frozen for histopathological analyses and immunofluorescent 
studies. Freshly cut lung sections (thickness of 5 μm) placed on poly-L-lysine-coated slides 
were stained with hematoxylin-eosin (HE) or Masson’ s trichrome (MT) in order to visualize 
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inflammatory or fibrotic lesions. The semi-quantitative elucidation of lung fibrotic changes 
was performed according to Ashcroft and co-workers’ method with a modification 
(Kobayashi et al., 2015). Briefly, under x100 magnification, the grade of lung fibrosis was 
scored on a scale of 0 to 8 (Hubner et al., 2008) by examining 10 randomly selected fields in 
each section (more than 4 sections/each group), and the average score was calculated. All 
sections were analyzed in a blinded manner by three independent researchers. In some 
experiments, sections were subjected to double staining with the anti-HIF-1α antibody in 
combination with the anti-αSMA antibody, rabbit anti-S100A4 antibody, rabbit anti-ionized 
calcium-binding adaptor molecule (Iba)-1 antibody (Wako), hamster anti-podoplanin/gp36 
antibody (Abcam), or rabbit anti-pro-surfactant protein (pro-SP)-C antibody (Tanaka et al., 
2014), and this was followed by a reaction with the appropriate fluorescein-conjugated 
secondary antibodies. 
In order to elucidate the effects of CsA or HIFi on BLM-induced lung injury, mice were 
intratracheally administered CsA dissolved in castor oil (0.5 mg/kg/day) or HIFi (0.1 
mg/kg/day) at 7, 8, and 9 dpi. Mice were divided into the following 6 groups: a control group 
(saline at 0 dpi, castor oil/saline at 7-9 dpi); CsA or HIFi-control group (saline at 0 dpi, CsA 
or HIFi at 7-9 dpi); BLM group (BLM at 0, castor oil/saline at 7-9 dpi); and BLM-CsA or 
HIFi group (BLM at 0 dpi, CsA or HIFi at 7-9 dpi), and differences in pathological outputs 
between these groups were estimated at the designated times. In some experiments, 
bronchoalveolar lavage fluid (BALF) was collected with 1 ml PBS using a 20-gauge catheter 
at 14 dpi. After centrifuging BALF at 400 x g for 10 min, the cell pellet was resuspended in 
PBS and subjected to a cell count using a hemocytometer. 
 
Measurement of soluble collagen.  Collagen contents in lung samples were measured using 
Sircol™ Soluble Collagen Assay kit (biocolor life science assays, Carrickfergus, UK) 
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according to the manufacturer’s protocol. In brief, the minced left lung samples were digested 
in 0.1 mg/mL pepsin/0.5 M acetic acid at 4˚C overnight. The digested samples were 
centrifuged to remove tissue debris, and the resulting supernatants were subjected to the kit.  
 
Statistical analysis.  Data are expressed as the mean ± S.E. Statistical analyses were 
conducted using Graphpad Prism Version 6 (GraphPad Software Inc., San Diego, CA). The 
significance of differences was assessed using the Student’s t-test or an analysis of variance 
(ANOVA) followed by Tukey’s test. P < 0.05 were considered significant. 
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4. RESULTS 
CsA prevented TGF-β1-induced FMD.  In HFL-1 cells, αSMA levels were detected under 
serum-starved conditions, and the treatment with 10 ng/ml TGF-β1 for 48 h markedly 
increased αSMA levels, as described previously (Kawashima et al., 2012). We examined the 
effects of several drugs (CsA, FK506, cyclophosphamide, AZA, rapamycin, hydrocortisone, 
and PFD) used clinically for TGF-β1-induced FMD by monitoring changes in the expression 
of αSMA, a marker for myofibroblasts (Hinz et al., 2007). Among them, only CsA 
dose-dependently exerted a significant counter effect on the TGF-β1-induced up-regulated 
expression of αSMA (in my main publication, Fig. 1A and Fig. S1). CsA significantly 
inhibited the expression levels of αSMA, even under the TGF-β1-free state. In the presence 
of 10 µM CsA, αSMA levels in cells stimulated with TGF-β1 were similar to control levels 
under the resting state, indicating that CsA exerts anti-FMD effects. The treatment with 5 mM 
PFD, an orally active drug approved for the treatment of IPF, slightly inhibited the 
TGF-β1-induced up-regulated expression of αSMA. However, its anti-FMD efficacy was 
weak and not significant, at least in our assay system (in my publication, Fig. S1). Although 
CsA and FK506 both act as inhibitors of CN, FK506 did not inhibit the TGF-β1-induced 
up-regulated expression of αSMA (in my publication, Fig. S1). The anti-FMD efficacy of 
CsA in comparison with FK506 was also investigated in WI-38 cells, another cell line of 
human lung fibroblasts. CsA significantly inhibited the TGF-β1-induced expression of not 
only αSMA, but also fibronectin, another myofibroblast marker (in my publication, Fig. 1, B 
and C). In contrast, the two markers up-regulated by TGF-β1 were not inhibited by the 
treatment of cells with FK506 (in my publication, Fig. 1D). Although a marked difference 
was observed in anti-FMD efficacy between CsA and FK506, both agents significantly 
inhibited the activity of CN in the lysate from WI-38 cells (in my publication, Fig. 1E).  
These results indicate that the anti-FMD effects of CsA are caused by the targeting of some 
molecules other than CN. Therefore, the mechanisms underlying the anti-FMD effects of CsA 
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were elucidated. 
 
HIF-1α was involved in TGF-β1-induced FMD.  TGF-β1 responses are mediated by the 
Smad pathway in various cells including lung fibroblasts (Rahimi and Leof, 2007). TGF-β 
receptor type I-phosphorylated Smad3 forms a complex with Smad4, translocates into the 
nucleus as a transcription factor and binds to the Acta2 (αSMA gene) promoter containing 
CAGA motifs, termed the Smad3-binding element, where the TGF-β1/Smad3 signaling axis 
regulates the expression of αSMA at the transcriptional level in myofibroblast differentiation 
(Hu et al., 2003). Consistent with this finding, SIS3, a specific Smad3 inhibitor, significantly 
inhibited the TGF-β1-induced up-regulated expression of αSMA in our FMD assay with 
WI-38 cells (in my publication, Fig. 2A). TGF-β1 augmented the phosphorylation of Smad3 
in WI-38 cells within 15 min of the stimulation, which was insensitive to the treatment with 
CsA (in my publication, Fig. 2B). These results indicate that the anti-FMD effects of CsA are 
not accompanied by the modulation of Smad3 dephosphorylation. 
In lung fibroblasts, it has been demonstrated that TGF-β1 responses are regulated by 
another transcription factor, HIF-1 (Abdul-Hafez et al., 2009; Zhou et al., 2011; Kottmann et 
al., 2012) and also that TGF-β1 regulates HIF-1α levels (Bardos and Ashcroft, 2005; 
D’Angelo et al., 2003). We investigated the contribution of HIF-1α to TGF-β1-induced FMD 
in WI-38 cells. Expression levels of HIF-1α markedly increased 3 and 6 h after the treatment 
of cells with TGF-β1 (in my publication, Fig. 3A). The inhibition of HIF-1α by its chemical 
inhibitor (HIFi) significantly decreased the TGF-β1-induced expression of αSMA and 
fibronectin (in my publication, Fig. 3B). The inhibitory effects of HIFi on TGF-β1-induced 
αSMA expression were replicated by the introduction of siHIF-1α into cells (in my 
publication, Fig. 3C). On the other hand, neither the TGF-β1-induced phosphorylation of 
Smad3 nor the TGF-β1-induced translocation of active Smad3 were affected by the treatment 
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of WI-38 cells with HIFi (in my publication, Fig. 3, D and E). Considering the function of 
HIF-1α as a transcriptional factor, the inhibitory effects of HIFi on TGF-β1-induced protein 
expression of αSMA and fibronectin could result from the changes in mRNA levels of the 
two key molecules in FMD. To evaluate this point and investigate whether CsA treatment 
also suppresses the TGF-β1-induced mRNA expression of αSMA (Acta2) and fibronectin 
(FN1), qPCR was performed with monitoring the inhibitory effects of SIS3 as indices. As 
shown in Fig. 3F in my publication, either treatment with HIFi or CsA significantly 
suppressed the TGF-β1-induced mRNA expression of Acta2 and FN1. 
In C6 glioma cells, a previous study showed that CsA stimulates PHD activity, 
specifically modifying Pro-564 within the oxygen-dependent degradation domain of HIF-1α, 
and triggered the VHL-dependent ubiquitin-proteasome pathway, leading to the 
destabilization of HIF-1α (D’Angelo et al., 2003). In the same study, FK506 did not function 
as a direct stimulator of PHD. In conjunction with our present results that only CsA was 
effective against TGF-β1/HIF-1α signaling-mediated FMD, we hypothesized that CsA may 
lower HIF-1α protein stability. Considering their established high transfection efficiency and 
endogenous PHD2 activity, HEK293T cells were used in a degradation assay of HIF-1α 
(Berchner-Pfannschmidt et al., 2008). As shown in Fig. 4A in my publication, 
HIF-1α-introduced cells showed a strong HIF-1α signal in immunoblotting. This HIF-1α 
expression was significantly decreased by the 30-min treatment of cells with 10 µM CsA, but 
not 10 µM FK506. The CsA-induced down-regulated expression of HIF-1α was canceled by 
the application of 10 µM MG-132, a proteasome inhibitor, to cells. The expressions of PHD2 
and VHL protein were not affected in this experimental condition (in my publication, Fig. 
4B). These results indicate that CsA exerts anti-FMD effects via the proteasome-mediated 
degradation of HIF-1α. 
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CsA and inhibition of HIF-1α-induced dedifferentiation of MyoLCs.  In addition to the 
inhibition of FMD, the induction of the dedifferentiation of established myofibroblasts may 
be a highly relevant strategy in therapies for progressive fibrotic disorders (Hecker et al., 
2011). Therefore, we investigated whether CsA induced the dedifferentiation of MyoLCs 
derived from the lungs of the patient with IPF. Primary cultured cells at passage 3 clearly 
showed immunoreactivity for αSMA, but not S100A4, a fibroblast marker, and expressed a 
markedly higher level of fibronectin than that in WI-38 cells (in my publication, Fig. 5, A and 
B), indicating that primary cells possessed the characteristics of myofibroblasts. In MyoLCs, 
the treatment with CsA induced a marked down-regulation in HIF-1α expression (in my 
publication, Fig. 5C). Immunoblotting and immunofluorescent studies clearly showed that 
CsA down-regulated the expression of αSMA and fibronectin in MyoLCs, which was 
replicated by the inhibition of HIF-1α (in my publication, Fig. 5, D and E). 
Therefore, the possibility of CsA exerting anti-FMD effects and myofibroblast 
dedifferentiation-promoting activity that are beneficial for pulmonary fibrosis was proven. 
This was also supported by additional in vitro observations that CsA, but not FK506 
significantly inhibited TGF-β1-induced epithelial-mesenchymal transition (EMT) associated 
with a decrease in E-cadherin expression in A549 cells (in my publication, Fig. S2). EMT is 
recognized as one of the mechanisms responsible for pulmonary fibrogenesis (Kasai et al., 
2005). Due to the suppressive effects of CsA on fibrosis, the anti-fibrotic effects of CsA were 
then examined in a BLM-induced lung injury model. 
 
CsA and inhibition of HIF-1α prevented BLM-induced lung injury.  In a mouse model with 
the single intratracheal administration of BLM, acute alveolitis and interstitial inflammation 
accompanied by the accumulation of leukocytes and pulmonary edema were induced within 
one week, and fibrotic lung lesions were clearly observed in patches at 7 dpi, which is termed 
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the early fibrotic stage. BLM-induced fibrotic responses including the synthesis of 
pro-fibrotic proteins such as αSMA and collagen subsequently progressed, and large parts of 
alveoli were obliterated with fibrous masses at 14 dpi (Kobayashi et al., 2015; Yamauchi et 
al., 2011). Consistent with previous findings, the up-regulation of αSMA in the lung was 
typically detected at 7 dpi, the level of which increased at least until 14 dpi (in my publication, 
Fig. S3A). At 7 dpi, but not 3 dpi, when the BLM-induced up-regulated expression of αSMA 
was detected, small fibrotic foci were sparsely observed in lung sections stained with HE (in 
my publication, Fig. S3B), indicating that this time point represents the plausible onset of the 
fibrotic stage. Prior to the BLM-induced up-regulated expression of αSMA, the expression of 
HIF-1α in the lung was induced at 3 dpi and sustained at least until 14 dpi (in my publication, 
Fig. S3A). The sustained induction of TGF-β1 mRNA was occasionally detected on 3 dpi 
(Gurujeyalakshmi et al., 1995), indicating that the TGF-β1/HIF-1α signaling pathway 
contributes to in vivo FMD. This was supported by an immunofluorescent study showing that 
HIF-1α-like immunoreactivity was mainly localized in αSMA+ myofibroblasts and S100A4+ 
fibroblasts in the lung at 7 dpi (in my publication, Fig. S3C, a and b). HIF-1α-like 
immunoreactivity was weakly observed in ionized calcium-binding adaptor molecule (Iba)-1+ 
macrophages, as previously reported (Ueno et al., 2011), but not in gp36+ type I or 
pro-surfactant protein (SP)-C+ type II alveolar epithelial cells (in my publication, Fig. S3C, 
c-e). Based on these results, BLM-treated mice received an intratracheal injection of CsA or 
HIFi at 7, 8, and 9 dpi when in the early fibrotic state (in my publication, Fig. 6A).  
At 14 dpi, the expression level of αSMA in the lung was significantly higher in the BLM 
group than in the control and CsA-control groups, and was lower in the BLM-CsA group (in 
my publication, Fig. 6B). In parallel with these phenomena, the BLM-induced up-regulated 
expression of HIF-1α was fully sensitive to the administration of CsA (in my publication, Fig. 
6C). Furthermore, the inhibition of BLM-induced αSMA expression by CsA was clearly 
19 
 
replicated by HIFi at 14 dpi. As shown in Fig. 6D in my publication, the expression level of 
αSMA in the lung was significantly higher in the BLM group than in the control and 
HIFi-control groups, and was significantly lower in the BLM-HIFi group. In order to 
elucidate whether changes in αSMA expression among the groups correlated with 
pathological outputs in the lung, lung sections from each group at 14 dpi were subjected to 
HE and MT (in my publication, Fig. 6E and F, respectively) staining. Fibrotic lesions 
including robust collagen deposition, thickening of the alveolar walls, and the accumulation 
of inflammatory cells were observed in lungs from the BLM group, and were markedly 
decreased in lungs from the BLM-CsA and BLM-HIFi groups. In contrast, no pathological 
changes were observed in the three control groups (control, CsA-control, and HIFi-control). 
These histopathological results were supported by both the modified Ashcroft scale analysis 
and the soluble collagen assay. BLM markedly and significantly increased the Ashcroft score 
and the collagen content over those in the three control groups, and they were significantly 
decreased by the application of CsA or HIFi (in my publication, Fig. 6G and H). Similarly, 
the numbers of total inflammatory cells in BALF at 14 dpi were significantly elevated by 
BLM, and this was significantly inhibited by the application of CsA or HIFi (in my 
publication, Fig. 6I). These results indicate that the CsA-sensitive HIF-1α pathway functions 
at least at the early fibrotic stage and contributes to the establishment of fibrosis in the 
BLM-induced lung injury model. In order to rule out the possibility that the CsA-sensitive 
HIFi pathway simply delays BLM-induced lung fibrotic formation, fibrosis read-outs were 
extended to 21 dpi. As shown in Fig. S4 in my publication, the BLM-induced up-regulated 
expression of αSMA was significantly attenuated by the application of HIFi, showing good 
parallelism with HIFi markedly ameliorating BLM-induced lung fibrosis at 21 dpi. 
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5. DISCUSSION 
Some patients with pulmonary fibrosis are treated with immunosuppressive drugs. 
However, their effects on FMD have not yet been studied in detail. Furthermore, treatments 
with immunosuppressive drugs occasionally lead to serious clinical issues such as renal 
dysfunction, which are in part due to the administration route and dosage. In the present study, 
we showed that CsA inhibited TGF-β1-induced FMD in human lung fibroblasts and reduced 
the established expression of αSMA and fibronectin in lung MyoLCs from a patient with IPF. 
These effects of CsA were mediated via the down-regulated expression of HIF-1α. We also 
demonstrated that the intratracheal administration of CsA or HIFi ameliorated pulmonary 
fibrosis in a BLM-induced lung injury model.  
 
CsA targets HIF-1α, which plays an important role in the TGF-β1 signaling pathway.  
Considering the mode of action of CsA as a CN inhibitor, we speculated that 
TGF-β1-induced FMD in human lung fibroblasts may be mediated in a CN-dependent 
manner. We confirmed the marked inhibition of CN activity in WI-38 cell lysates treated with 
CsA or FK506. However, CsA, but not FK506 exerted anti-FMD effects in HFL-1 and WI-38 
cells, suggesting that CN activity does not function in TGF-β1-induced FMD in human lung 
fibroblasts. We then focused on HIF-1α in the TGF-β1-evoked signaling pathway and 
pulmonary fibrosis. In vitro, TGF-β1 has been shown to inhibit the expression of PHD2 to 
increase HIF-1α (Abdul-Hafez et al., 2009; Ueno et al., 2011; McMahon et al., 2006; Han et 
al., 2013). Furthermore, under our experimental conditions, TGF-β1 and BLM induced the 
expression of HIF-1α in vitro and in vivo, respectively. In both cases, an increase in HIF-1α 
was achieved prior to the induction of αSMA and formation of fibrotic foci, suggesting that 
HIF-1α is a cause of FMD. Similar to the CsA treatment, the inhibition of HIF-1α by HIFi 
and its siRNA markedly attenuated the TGF-β1-induced expression of αSMA in WI-38 cells. 
These results were supported by previous findings showing that HIF-1α interacts with 
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hypoxia response elements in the αSMA promoter as a positive regulator (Han et al., 2013; 
Watanabe et al., 2014).  
Consistent with previous findings (D’Angelo et al., 2003; Kim et al., 2008), we observed 
that transiently overexpressed HIF-1α in HEK293 cells was significantly decreased by the 
application of CsA, and this was canceled when cells were treated with CsA concomitantly 
with MG132. Therefore, the anti-FMD effects of CsA may be mediated by promoting the 
proteasomal degradation of HIF-1α; although we did not investigate whether CsA changed 
PHD2 activity under our experimental conditions, at least the protein levels of PHD2 and 
VHL were not changed. Moreover, HIF-1α positively regulates EMT in various cells 
including A549 human adenocarcinomic alveolar epithelial cells (Zhu et al., 2016). The 
number of pulmonary epithelial cells in the lungs of IPF patients was shown to decrease due 
to EMT and apoptosis (Thannickal and Horowitz, 2006). In the present study, the CsA 
treatment inhibited TGFβ1-induced reductions in E-cadherin, a marker of epithelial cells that 
decreases when EMT occurs. 
 
CsA and HIFi may induce the dedifferentiation of MyoLCs. 
  In recent studies, two types of myofibroblasts have been proposed: proto-myofibroblasts 
(an intermediate state between fibroblasts and differentiated myofibroblasts) and 
differentiated myofibroblasts. The former expresses less αSMA and is capable of proliferating, 
whereas the latter expresses αSMA more strongly in extensively developed actin stress fibers 
and is nearly incapable of proliferating (Tomasek et al., 2002; Driesen et al., 2014). In the 
MyoLCs used in the present study, we observed the established expression of αSMA and 
fibronectin, similar to other reported primary (myo-) fibroblasts derived from the lungs of 
patients with pulmonary fibrosis (Reddy et al., 2014). Although the αSMA was not 
incorporated into actin stress fibers, when MyoLCs were cultivated with TGF-β1, most of 
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αSMA in MyoLCs co-localized with actin stress fibers (data not shown). In addition, cells 
exhibited proliferative ability with serum (cell doubling time: 72-84 h, n=9), similar to 
normal fibroblasts. Based on these results, MyoLCs are likely characterized as 
proto-myofibroblasts. Even if MyoLCs are not fully differentiated myofibroblasts, they were 
sufficiently aggressive to cause severe fibrosis in the patient’s lungs. The expression of 
myofibroblast markers was significantly decreased by the treatment of MyoLCs with CsA or 
HIFi. Recent studies have demonstrated that the dedifferentiation of myofibroblasts 
associated with the reduced expression of αSMA and ECM proteins may be induced in lung 
fibroblasts under certain experimental conditions (Reddy et al., 2014; Garrison et al., 2013; 
Penke et al., 2014). Hence, in addition to anti-FMD effects, CsA and HIFi may also promote 
the dedifferentiation of myofibroblasts, at least in vitro. Basically, blocking an autocrine loop 
with the positive feedback of TGF-β1 appears to be one of the necessary, but not sufficient 
steps for inducing the dedifferentiation of myofibroblasts (Hecker et al., 2011; Kosla et al., 
2013). However, the detailed molecular mechanisms remain unclear. 
 
Anti-fibrotic effects of CsA and HIFi in BLM-induced pulmonary fibrosis model mice. 
We found that HIF-1α was induced the latest from 3 dpi and then clearly localized in 
fibrotic foci expressing αSMA at 7 dpi. Based on our in vitro results, since CsA may lead to 
the loss of function of HIF-1α, the administration of CsA or HIFi at the fibrotic stage of 
BLM-induced pulmonary injury (from 7 dpi) may exert therapeutic effects in vivo. In 
addition, we considered this administration protocol to be reasonable and practical. Most IPF 
patients presenting to clinicians for the first time with subjective symptoms show a reduced 
forced vital capacity, suggesting the early fibrotic stage (King et al., 2001b). As expected, 
BLM-induced lung fibrosis was significantly inhibited by the application of CsA or HIFi. We 
have investigated that the concomitant administration of CsA and HIFi did not show any 
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synergistic inhibitory effect on BLM-induced lung fibrosis (data not shown), supporting the 
notion that CsA may exert anti-FMD effects via the proteasome-mediated degradation of 
HIF-1α. 
Although the administration of PGE2 was previously reported to be capable of 
dedifferentiating myofibroblasts in vitro (Garrison et al., 2013; Wettlaufer et al., 2016), it had 
no therapeutic effect on pulmonary fibrosis when administered at the fibrotic stage of 
BLM-induced lung injury (Dackor et al., 2011). Similar to the case described in the present 
study, the endogenous agonist of peroxisome proliferator-activated receptor γ (PPARγ), 
nitrated fatty acid, which exhibits anti-FMD and myofibroblastic dedifferentiation activities, 
may inhibit BLM-induced pulmonary fibrosis following its intratracheal administration at the 
fibrotic stage (Reddy et al., 2014). Therefore, the amelioration of BLM-induced lung fibrosis 
by CsA or HIFi may be achieved in part by dedifferentiating myofibroblasts; however, more 
detailed studies are warranted. 
In our studies, the intratracheal administration of a low dose of CsA (0.5 mg/kg/day) 
succeeded in ameliorating BLM-induced pulmonary fibrosis.  On the other hand, the 
administration of 50 mg/kg/day CsA through an unknown route also suppressed 
BLM-induced lung fibrosis by blocking CD147 in macrophages (Geng et al., 2014). 
Therefore, the effects of CsA on various types of cells in lung tissues need to be examined 
more. 
Although various drug candidates have been developed, there is still no effective drug for 
the treatment of pulmonary fibrosis that prolongs survival. Greater effectiveness may be 
achieved if the drug exerts anti-FMD effects and the ability to promote the dedifferentiation 
of myofibroblasts. Therefore, the results of the present study will be useful for developing 
novel therapeutic drugs.  
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10. TABLE AND FIGURE 
 
 
Table 1. The list of primary antibodies used in this study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Type Clone Provider
α-smooth muscle actin (αSMA) mouse monoclonal 1A4 Sigma-Aldrich
β-tubulin mouse monoclonal TUB2.1 Sigma-Aldrich
β-actin mouse monoclonal AC-15 Sigma-Aldrich
fibronectin mouse monoclonal IST-3 Sigma-Aldrich
ED-A fibronectin mouse monoclonal IST-9 Santacruz
phospho-Ser
423/425
-Smad3 (pSmad3) rabbit monoclonal N.A. Cell Signaling Technology
Smad3 rabbit monoclonal N.A. Cell Signaling Technology
E-cadherin mouse monoclonal 36 BD Biosciences
hypoxia-inducible factor 1α (HIF-1α) mouse monoclonal H1alpha67 NOVUS biologicals
prolyl hydroxylase 2 (PHD2) mouse monoclonal H-8 Santa Cruz
von Hippel-Lindau (VHL) mouse monoclonal VHL40 Santa Cruz
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mouse monoclonal 5A12 Wako
S100 calcium-binding protein A4 (S100A4) rabbit polyclonal N.A. Abcam
ionized calcium-binding adaptor molecule (Iba)-1 rabbit polyclonal N.A. Wako
podoplanin/gp36 hamster monoclonal RTD4E10 Abcam
pro-surfactant protein (pro-SP)-C rabbit polyclonal N.A. provided by Dr. Kasuya Y
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Figure 1. Current model for pathogenesis of IPF 
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11. POSTSCRIPT 
1. Mode of action of CsA in promoting the activity of PHD2 
CsA needs to form complex with an immunophilin, cyclophilin A, when it inhibits 
calcineurin. However, it is not known if CsA needs cyclophilin A as well in the case of 
promoting the activity of PHD2.  
To answer the question, the following experiments would be needed: ① treating WI-38 
cells with DEBIO-025, an analogue of CsA, which cannot bind to cyclophilin A (Paeshuyse 
et al., 2006), and then test if DEBIO-025 can inhibit TGF-β1-induced FMD, ② examining 
the effect of CsA in WI-38 cells that carry much less amount of cyclophilin A by RNA 
interference, or ③ in vitro PHD2 activity assay using recombinant human PHD2 protein, its 
substrates, and cyclosporine A. At least, in vitro PHD2 activity was increased by CsA in 
homogenized cell lysates (D’Angelo et al., 2003, listed in “6 References”. 
 
2. Dedifferentiation from MyoLCs 
The MyoLCs treated with HIFi for 48 h expressed S100A4, a marker protein for 
fibroblasts, supporting the possibility of dedifferentiation by inhibiting HIF-1α (unpublished 
data). To further examining what is occurred during the dedifferentiation, gene expression in 
the cells treated with or without CsA and HIFi analysis should be performed. It was reported 
that PGE2 reversed the expression of genes up-regulated by TGF-β1 (Wettlaufer et al., 2016, 
listed in “6. Reference”). However, concerning that inhibition of TGF-β1 signaling is not 
enough for inducing dedifferentiation (Kosla et al., 2016, listed in “6. Reference”), inhibition 
of HIF-1α pathway might affect other gene expression besides TGF-β1 signaling.  
It is also required to have other maker proteins for fibroblasts. In my study, S100A4 was 
used as a marker protein for fibroblasts. In general, it is preferable to use plural markers when 
identifying the character of the cells, however there is not many specific marker proteins 
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available for fibroblasts. Comparing gene expressions between fibroblasts and myofibroblasts 
would be helpful to find appropriate specific genes (proteins) as marker proteins for 
fibroblasts. It is important to identify the origin of myofibroblasts in order to understand the 
pathogenesis of IPF because recently it is thought that myofibroblasts can be differentiated 
from various types of cells as described in “5. Discussion” (also, Stempien-Otero et al., 
2016). 
 
3. Roles of inflammation/inflammatory cells  
   Inflammation was thought to be important in development of IPF. Currently, it is widely 
accepted that inflammation and fibrosis should be considered as different phenomena. Still, 
emerging numbers of reports suggesting the positive correlation between some populations of 
macrophages and fibrosis (Sato T et al., 2017). Among them, SatM (Segregated Nucleus 
atypical monocytes) were shown to have strong ability to promote BLM-induced pulmonary 
fibrosis in mice (Sato T et al., 2017). CCAAT/enhancer-binding protein (C/EBP) β is 
essential for differentiate the progenitor cells of SatM into SatM. However, if CsA and HIFi 
inhibit C/EBPβ is unknown.  
On 14 dpi, the total cell number in BALF (bronchoalveolar lavage fluid) was increased in 
BLM group compared with control. Those were decreased in BLM/CsA group and 
BLM/HIFi group (data not shown). The results indicated that treatment with CsA or HIFi 
suppressed inflammation on 14 dpi. Hence, it is difficult to exclude the possibility that CsA 
or HIFi restored fibrosis by inhibiting inflammatory response. However, according to the 
results in vitro and concerning that inflammation mainly occurs within a week, it is more 
reasonable to think that anti-inflammatory effects were not their main effect in my 
experimental condition. 
 
40 
 
4. Which would be better treatment agent for IPF, CsA or inhibitor of HIF-1α?  
   CsA is clinically used drug for decades, thus its metabolic pathway and safety in human 
use has been confirmed. Concerning the long process of drug approval, CsA has slightly less 
barrier than inhibitors of HIF-1αbefore they would become treatments for IPF. However, in 
this case, the change in formulation will be necessary. In the case of inhalant, to let it reach 
the alveoli, the particle size should be around 5 µm. Larger or smaller particles will be 
trapped before it reaches alveoli or come out with exhaled breath.  
   Although the current disadvantage of inhibitor of HIF-1α is that there is no clinically used 
drug as a HIF-1α inhibitor, recently, some compounds are in clinical trials for cancer: 
2-Methoxyestradiol (Phase 2), BAY 87-2243 (Phase 1), PX-478 2HCl (Phase 1). If one 
(some) of them will be approved, the drug could be extended its application to IPF. In 
addition, blocking HIF-1α seems preferable than using CsA in terms of side-effects. HIF-1α 
is essential for the embryo development and HIF-1α knock out mouse dies by E11 mainly due 
to cardinal abnormalities and failure of neural tube closure (Iyer et al., 1998). On the other 
hand, in adult, it usually degraded and only accumulates in where hypoxia occurs (i.g. 
ischemic region, cancer tissues, fibrotic region) or where HIF-1α-stabilizing signal is running. 
Therefore, inhibition of HIF-1α seems less harmful and more favorable than CsA. 
 
5. The results could be applied to fibrosis in other tissues? 
   TGF-β1 is involved in not only pulmonary fibrosis but also other fibrosis such as liver 
fibrosis, kidney fibrosis, and skin fibrosis (Klass et al., 2009). In kidney fibrosis, the 
expression level of HIF-1α is upregulated (Liu et al., 2017). It is reasonable that HIF-1α is 
upregulated in fibrotic region where the cell density is increased. Therefore, given that 
TGF-β1/HIF-1α axis plays an important role in other kinds of fibrosis as well as pulmonary 
fibrosis, treatment with CsA or HIFi would restore the fibrosis. However, for other fibrosis, 
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the optimization of the administration route of the drug for each tissues will be required. 
   One concern in the case of kidney fibrosis is that CsA itself might cause renal fibrosis. 
Although the risk will be high when the patient uses CsA more than 2 years, the continuous 
monitoring of renal function is necessary. Probably, for the treatment for kidney fibrosis, 
HIF-1α inhibitor will be a better choice. 
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